Dose-escalation Study of Lupartumab Amadotin (BAY1129980)
NCT02134197
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
69
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
Lupartumab Amadotin (BAY1129980)
Sponsor
Bayer